A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects

Inclusion Criteria: * Healthy, as judged by the investigator or sub-investigator based on the results of physical examinations and all tests * Body weight: male: ≥45.0 kg, \<85.0 kg; female: ≥40.0 kg, \<75.0 kg * BMI (at screening): ≥17.6, \<30.0 Exclusion Criteria: * Use of any other investigational drug in another clinical study or a post-marketing clinical study within 120 days before the administration of the study drug * Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the screening assessment. * Any surgical intervention (including tooth extraction) or trauma within 90 days before hospitalization until the administration, or plan of any surgical intervention within 10 week after the final administration * A deviation from the normal reference range of blood pressure, pulse rate, body temperature, or 12-lead ECG * PT or aPTT on blood coagulation tests outside the upper or lower reference limits (PT: 9.9 to 15.4 sec.; aPTT: 22.5 to 49.5 sec.) * Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days before the study * Concurrent or previous hepatic disease (e.g. viral hepatitis, drug-induced liver injury) * Concurrent or previous heart disease (e.g. congestive heart failure, angina pectoris, arrhythmia requiring treatment) * Concurrent or previous respiratory disease (e.g. serious bronchial asthma, chronic bronchitis; except for a history of childhood asthma) * Concurrent or previous renal disease (e.g. acute renal failure, glomerulonephritis, interstitial nephritis; except for a history of calculus) * Concurrent or previous malignant tumor * Excessive smoking or drinking habit \[measure of "excessive": alcohol: average 45 g/day (a 633 mL bottle of beer contains 25 g of alcohol, and 180 mL of Japanese sake contains 22 g of alcohol), smoking: average 20 cigarettes/day\] * Previous treatment with YM150